Advicenne

Advicenne, founded in 2007 and headquartered in Nîmes, France, is a late-stage biopharmaceutical company focused on developing innovative treatments for unmet medical needs in nephrology and niche neurology indications. The company's lead drug candidate, ADV7103, is currently undergoing late-stage clinical trials for two specific conditions: distal renal tubular acidosis (dRTA) and cystinuria. Advicenne aims to create pediatric-friendly therapeutics that enhance the quality of life for patients from early childhood through adulthood, particularly in the realm of orphan renal diseases.